Once Daily Administration Of The Sglt2 Inhibitor, Empagliflozin, Attenuates Markers Of Renal Fibrosis Without Improving Albuminuria In Diabetic Db/Db Mice (Vol 6, 26428, 2016)
SCIENTIFIC REPORTS(2016)
摘要
A Nature Research Journal
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要